Although the Model for End-Stage Liver Disease sodium (MELD Na) score is now used for liver transplant allocation in the United States, mortality prediction may be underestimated by the score. Using aggregated electronic health record data from 7834 adult patients with cirrhosis, we determined whether the cause of cirrhosis or cirrhosis complications was associated with an increased risk of death among patients with a MELD Na score ≤15 and whether patients with the greatest risk of death could benefit from liver transplantation (LT). Over median follow-up of 2.3 years, 3715 patients had a maximum MELD Na score ≤15. Overall, 3.4% were waitlisted for LT. Severe hypoalbuminemia, hepatorenal syndrome, and hepatic hydrothorax conferred the greatest risk of death independent of MELD Na score with 1-year predicted mortality >14%. Approximately 10% possessed these risk factors. Of these high-risk patients, only 4% were waitlisted for LT, despite no difference in nonliver comorbidities between waitlisted patients and those not listed. In addition, risk factors for death among waitlisted patients were the same as those for patients not waitlisted, although the effect of malnutrition was significantly greater for waitlisted patients (hazard ratio 8.65 [95% CI 2.57-29.11] vs. 1.47 [95% CI 1.08-1.98]). Using the MELD Na score for allocation may continue to limit access to LT.
Introduction
Liver allocation based on the Model for End-Stage Liver Disease (MELD) was implemented in the United States in 2002 and prioritizes access to liver transplantation (LT) based on medical urgency (1) . As an objective measure, MELD was a significant improvement from the prior allocation policy, which used the Child-Turcote-Pugh score and waiting time (2) . However, despite present MELDbased allocation policy, the annual mortality on the waiting list remains substantial, with %2000 patients dying and another 1000 patients removed because they are too sick for transplant (3) . Although many of these deaths are due to the shortage of organs, some are attributable to imperfect mortality risk prediction.
risk factor for mortality in end-stage liver disease (ESLD) independent of the MELD score (5) . Therefore, since January 2016, the MELD sodium (MELD Na) score has been used for liver allocation instead of MELD (6) . ESLD patients with a low MELD score are the predominant beneficiaries of this new liver allocation system because the greatest improvement in mortality risk prediction using MELD Na is seen in patients with a low MELD score and low serum sodium levels (5) .
Other predictors of mortality, besides serum sodium, that confer significant risk of death independent of the MELD score have been reported previously (7, 8) . Ascites (7) , for instance, and hepatic encephalopathy (8) , albeit subjective, are complications of ESLD that portend a poor outcome despite a low MELD score. It remains unknown, however, whether mortality risk continues to be underestimated in specific subgroups of patients with cirrhosis and low MELD Na, given the improvement in risk prediction using the MELD Na score instead of MELD.
A large epidemiological study of all patients with cirrhosis is limited by the absence of a national registry. To date, cirrhosis patient data have largely been provided by single institutions and by the national liver transplant registry (4, 5, 8) , which only captures patients listed for transplantation. This data source predominantly includes patients with MELD Na scores >15. Novel data sources that consist of wide-ranging populations of patients with liver cirrhosis can improve on the limitations of current data sources (9) . Consequently, in the absence of a national cirrhosis database, this study used aggregated electronic health record (EHR) data (HealthLNK) (10) from multiple health care networks encompassing the greater Chicago metropolitan area to determine whether subgroups of patients with cirrhosis and MELD Na ≤15 continue to be disadvantaged by the current MELD Nabased liver allocation system, thereby limiting their access to life-saving LT.
Materials and Methods
This retrospective cohort study of patients with liver cirrhosis was conducted between January 1, 2006, and December 31, 2012, and was approved by the Northwestern University institutional review board (IRB number STU00104145).
Data sources
Three sources of data were used: HealthLNK (10), United Network for Organ Sharing (UNOS) (11) , and the Social Security death master file (12) .
The HealthLNK Data Repository is an assembly of EHRs (deidentified) from six health care institutions: five large academic medical centers (Northwestern Medicine, University of Chicago Hospitals and Clinic, Rush University Medical Center, University of Illinois at Chicago Medical Center, and Loyola University Medical Center) and one large academic safety net health care system (Cook County Health and Hospitals System) (10) . The HealthLNK Data Repository currently contains records for encounters between January 1, 2006, and Dec 31, 2012, for patients residing in the city of Chicago and surrounding suburbs. Data provided by the various institutions included demographics, diagnoses, medications, laboratory values, and procedures (10) .
UNOS provided data about LT including waiting list status and transplant date (11) . Death dates were obtained from the Social Security death master file for Illinois (12) .
Study population
Patients with liver cirrhosis and aged ≥18 years were identified using International Classification of Diseases, Ninth Revision (ICD-9) codes 571.2 or 571.5 or 571.6, which were validated previously (13) (14) (15) .
Among patients identified with liver cirrhosis, MELD and MELD Na scores were calculated from multiple laboratory test results in accordance with recent Organ Procurement and Transplantation Network rules (16) . Median international normalized ratio, creatinine, bilirubin, and sodium laboratory values were determined for each month. Patients on warfarin, those with hepatocellular carcinoma, and those for whom MELD and MELD Na scores could not be calculated were excluded.
The study population was then divided into three groups based on their highest MELD and MELD Na scores achieved during the study period: (i) low MELD Na, with maximum MELD and MELD Na scores ≤15 (i.e. MELD and MELD Na scores were never >15); (ii) mixed MELD, with a maximum MELD score ≤15 but a MELD Na score >15; and (iii) high MELD, with MELD and MELD Na scores >15. This study is focused on the low MELD Na group because these patients are less likely to be listed for LT because of their low MELD Na scores. Factors associated with an increased risk of mortality independent of MELD Na score were assessed in these patients only. The mixed MELD group was used to assess the effect of low serum sodium on mortality among patients with a MELD score ≤15. Mortality rates among the three groups were compared to confirm the effect of an increasing MELD Na score on mortality.
Complications of cirrhosis were defined using various combinations of ICD-9 codes, Current Procedural Terminology (CPT) codes, medications, and laboratory values, using previously validated methods (17) . The definitions used to define the study population and complications of cirrhosis are provided in the Appendix. To ascertain non-liver-related morbidity, the Elixhauser comorbidity index (18) was adapted and used.
Data analysis
A summary of demographic and clinical characteristics is presented as mean and standard deviation or median and interquartile range for continuous variables. Categorical variables are presented as number and percentage.
Data were retrieved for patients during the study period (January 1, 2006, to December 31, 2012), beginning with the first ICD-9 code for cirrhosis (defined above) until death, LT, or end of the study period. The primary end point of the study was defined as all-cause mortality, with LT treated as a competing risk for death.
The predicted cumulative incidence function of death over time among the three groups was plotted and subdistribution hazards were compared using the Fine and Gray methods (19) .
A multivariate Fine and Gray subdistribution hazards model (20) was fitted to determine factors associated with mortality in the low MELD Na group independent of MELD Na score. Covariates were chosen for inclusion in the multivariate model if the observed univariate association was significant with a p-value <0.05 and if the covariate was deemed by author consensus to be potentially clinically significant. The multivariate model was adjusted for age, gender, race, insurance status, Elixhauser comorbidity index (18) , and maximum MELD Na score. A p-value <0.05 was considered significant in the final model.
Subgroup and further analysis
First, to assess whether patients with low MELD Na on the transplant waitlist had similar risk factors for death compared with nonwaitlisted patients, a Fine and Gray subdistribution hazards model using interaction terms was used. We adopted this approach to assess whether risk factors were the same in the two populations and to determine whether the relative effects of each risk factor differ depending on whether a patient is on the transplant waitlist. Second, to assess whether patients who possess risk factors that confer an increased risk of death independent of MELD Na score could potentially benefit from LT in terms of survival, the predicted probability of death at 1 year was calculated (using cumulative incidence functions) for each complication of cirrhosis with a hazard ratio (HR) >1.1 obtained from the multivariate subdistribution hazards model. Recent data demonstrate that living donor LT in the United States has a 1-year survival probability of 90.32% (21) . Consequently, a subgroup of patients with cirrhosis complications who had a 1-year predicted mortality risk ≥14% was selected (the cutoff of 14% was determined, following author consensus, as a mortality risk reasonably greater than %10% seen following living donor LT). This subgroup was stratified by LT waitlist status and compared by age, gender, insurance, etiology of cirrhosis, Elixhauser score, and MELD Na score, using two sample ttests, chi-square test, Fisher exact test, and the Wilcoxon rank sum test, as appropriate.
Analysis was performed using SAS version 9.4 (SAS Institute Inc., Cary, NC).
Results

Study population
A total of 10 302 adult patients with liver cirrhosis and at least one MELD or MELD Na score were identified. Of these, 782 (8%) patients were on warfarin, 1668 (16%) patients had hepatocellular carcinoma, and 18 (0.2%) patients had an abnormal time-censoring variable (i.e. an event occurred before the appearance of the ICD-9 code for cirrhosis) and thus were excluded, resulting in a study population of 7834 patients. Of these, 3715 (47%) were in the low MELD Na group; 484 (6%) were in the mixed MELD group, and 3635 (46%) patients were in the high MELD group. A comparison of demographic and clinical characteristics among the three groups is provided in Table 1 . Figure 1 shows the cumulative incidence of death having accounted for LT as a competing risk. The maximum length of follow-up was 7 years with a median follow-up time of 2.3 years. Cumulative incidence of death in the low MELD Na group was 4.7% (95% CI 4.1-5.5%) at 1 year, 12.1% (95% CI 10.9-13.3%) at 3 years, and 18.6% (95% CI 16.9-20.4%) at 5 years. Improved mortality prediction using MELD Na instead of MELD is demonstrated in the mixed MELD group because patients with MELD ≤15 but MELD Na >15, due to low serum sodium, have an increased cumulative incidence of death.
Predicted mortality
Risk factors associated with mortality in the low MELD Na group Results from univariate subdistribution hazards models are presented in Table S1 . Serum albumin consistently <2.8 g/ dL (severe hypoalbuminemia) or between 2.8 and 3.5 g/dL (moderate hypoalbuminemia), hepatorenal syndrome, hepatic hydrothorax, transjugular intrahepatic portosystemic shunt (TIPS), spontaneous bacterial peritonitis, ascites, malnutrition, hepatic encephalopathy, maximum platelet count ≤50 9 10 9 /L or between 50 and 100 9 10 9 /L, alcoholic cirrhosis, portal hypertension, MELD Na score, and Elixhauser comorbidity index (16) were all associated with a statistically significant increase in mortality risk. Nonalcoholic steatohepatitis (NASH) cirrhosis and cholestatic cirrhosis were associated with a statistically significant reduced mortality risk.
Jaundice, the presence of esophageal varices without bleeding, variceal bleeding, hepatitis B, and hepatitis C were not statistically significant. Hepatopulmonary syndrome was excluded from analysis because only four patients (0.1%) in the low MELD Na group had this risk factor, and imprecise estimates were obtained from the subdistribution hazards model.
The multivariate subdistribution hazards model is shown in Figure 2 . All significant univariate predictors and the nonsignificant predictors listed above (determined to be clinically significant by the authors) were included in the model. After adjusting for age, gender, race, insurance, MELD Na, and Elixhauser comorbidity index, the most significant predictors of mortality were severe hypoalbuminemia (HR 5.0; p < 0.0001) and moderate hypoalbuminemia (HR 3.0; p < 0.0001). Other important predictors of mortality include hepatic hydrothorax, ascites, and malnutrition. In this model, hepatorenal syndrome was not statistically significant (p = 0.06); however, in the subsequent model in which interaction terms were introduced, a statistically significant p-value (p = 0.04) for hepatorenal syndrome was observed. We thus considered hepatorenal syndrome a statistically significant predictor of mortality. A diagnosis of NASH (p = 0.003), cholestatic cirrhosis (p < 0.0001), and the presence of esophageal varices without bleeding (p = 0.03) were associated with a reduced risk of death. Predictors that were not statistically significant are provided in Table S2 . TIPS was noted to convey an increased risk of death in the univariate model (HR 2.8; p = 0.03). A non-statistically significant reduced risk of death for TIPS was observed in the multivariate model (HR 0.4; p = 0.38).
Assessment of whether risk factors differ depending on transplant waitlist status Among patients with low MELD Na, 3.4% (n = 125) were waitlisted for LT. Risk factors for death among patients on the transplant waitlist were the same as the risk factors for death among those not on the transplant waitlist; however, the effect of hepatic hydrothorax and malnutrition differed by waitlist status, as shown by statistically significant interaction terms (Figure 3 ). Hepatic hydrothorax is associated with an increased risk of death for those not waitlisted for LT; however, a non-statistically significant association was observed for those on the waitlist. In contrast, malnutrition was associated with significantly greater risk of death among waitlisted patients than among nonwaitlisted patients.
Potential for LT
Cumulative incidence functions for death up to 1 year for risk factors obtained from the multivariate subdistribution hazards model are shown in Figure 4 . One-year mortality following living donor LT in the United States is %10% (21).
Predicted 1-year mortality of 4.7% was seen in the low MELD Na group overall, as stated earlier. Patients with severe hypoalbuminemia, however, had 1-year predicted mortality of 22.9% (95% CI 17-29%), whereas those with moderate hypoalbuminemia had 1-year predicted mortality of 9.6% (95% CI 7.3-12.1%). Predicted 1-year mortality for patients with hepatorenal syndrome was 23.5% (95% CI 6.9-45.6), with hepatic hydrothorax was 16.5% (95% CI 11.4-22.3%), with malnutrition was 11.5% (95% CI 8.4-15.1%), and with ascites was 11.4% (95% CI 8.4-14.2%).
Patients with severe hypoalbuminemia, hepatorenal syndrome, or hepatic hydrothorax composed 9.7% of the low MELD Na group and were considered to be at high risk of death (1-year mortality ≥14%). Among this highrisk subgroup, only 4.2% (n = 15) were waitlisted for LT. When the high-risk subgroup was further stratified by transplant waitlist status, no statistically significant differences were seen between those listed and those not listed for LT in terms of age, gender, insurance status, or Elixhauser comorbidity index. Those listed for LT had a higher MELD Na score and were more likely to have cholestatic disease, as shown in Table 2 .
Discussion
Although an improvement over MELD, mortality prediction is still underestimated for important subgroups of patients with liver cirrhosis by using the MELD Na score. These subgroups include patients with hypoalbuminemia, hepatorenal syndrome, hepatic hydrothorax, malnutrition, and ascites. The recent adoption of the MELD Na score for liver allocation in the United States will thus continue to have important consequences for these subgroups of Figure 1 : Predicted mortality of patients with liver cirrhosis. Cumulative incidence function of mortality when treating liver transplantation as a competing risk for three groups of patients with liver cirrhosis. Predicted 1, 3, and 5-year mortality for each group is shown. If both the highest MELD and MELD Na scores were ≤15, patients were stratified into a low MELD Na cohort; if the highest MELD score was ≤15 but the highest MELD Na score was >15, patients were grouped in a mixed MELD cohort; and if both the highest MELD and MELD Na scores were >15, patients were placed in a high MELD cohort. Gray's test for equality of cumulative incidence function shows a statistical difference between the three groups (p < 0.0001). MELD, Model for End-Stage Liver Disease; MELD Na, Model for End-Stage Liver Disease sodium. The figure demonstrates the hazard ratios (HRs) for risk factors for mortality determined by the multivariate subdistribution hazards model among patients with MELD Na scores ≤15 (low MELD Na). The model is adjusted for age, gender, race, insurance, Elixhauser score, and maximum MELD Na score. Severe hypoalbuminemia is defined as maximum serum albumin <2.8 g/dL during the study period. Moderate hypoalbuminemia is defined as maximum serum albumin 2.8-3.5 g/dL during the study period. In this model, hepatorenal syndrome is not statistically significant; however, in a subsequent model (Figure 3 ) where interaction terms for transplant waitlist were introduced, the main effect of hepatorenal syndrome was observed to be statistically significant (p = 0.0414; HR 3.27, 95% CI 1.048-10.23). MELD Na, Model for EndStage Liver Disease sodium; NASH, nonalcoholic steatohepatitis.
patients. For the broader population of patients with cirrhosis and a low MELD Na score, access to LT is the issue of concern. In contrast, for those waitlisted, underestimation of death on the waitlist will persist.
This study used population-based data and is distinct from other studies. By using data from a large population of patients with liver cirrhosis, we found that very few patients with low MELD Na scores are waitlisted for LT, even though %10% possess risk factors that confer 1-year mortality greater than that of living donor LT.
Furthermore, among patients with low MELD Na at high risk, only %4% were waitlisted. The comparison between those waitlisted and those not waitlisted in this subgroup showed that waitlisted patients were more likely to have higher MELD Na scores and to have a diagnosis of cholestatic disease. No differences in age, gender, nonliver comorbidities, or insurance status between the two groups were observed. Consequently, it is likely that many patients with low MELD Na are not currently listed for LT who could benefit from the procedure. In fact, many may not even undergo evaluation for LT. †Statistically significant interaction term. The figure demonstrates the hazard ratios (HRs) for risk factors for mortality determined by the subdistribution hazards model among patients with MELD Na scores ≤15 according to transplant waitlist status. Overall risk factors for patients on the waitlist were the same as risk factors for those not waitlisted; however, the effect of hepatic hydrothorax and malnutrition differed based on whether an individual was on the liver transplant waitlist. The model is adjusted for age, gender, race, insurance, Elixhauser score, and maximum MELD Na score. Severe hypoalbuminemia is defined as maximum serum albumin <2.8 g/dL during the study period. Moderate hypoalbuminemia is defined as a maximum serum albumin 2.8-3.5 g/dL during the study period. MELD Na, Model for End-Stage Liver Disease sodium; NASH, nonalcoholic steatohepatitis.
The American Association for the Study of Liver Diseases guidelines from 2013 recommend that "the evaluation for liver transplant should be considered once a patient with cirrhosis has experienced an index complication such as ascites, hepatic encephalopathy, or variceal hemorrhage or hepatocellular dysfunction resulting in a MELD score equal or greater than 15" (22) . As a result, this cutoff of 15 has largely been viewed by clinicians as the threshold for waitlisting a patient (23) . In this study, however, the highest median MELD Na score achieved among the low MELD Na group, after median follow-up of 2.3 years, was 9 with an interquartile range of 8-11. Consequently, these patients died without ever having a MELD Na score of at least 15. The MELD allocation policy has had a significant effect on selection of patients for LT that cannot be ignored. This negative effect is likely to persist, despite the current use of the MELD Na score for allocation instead of MELD. Importantly, additional new changes in policy, such as regional sharing of organs for patients with MELD Na >35 (24), will likely further decrease the listing of patients with MELD Na <15. Due to the regional disparity in organ availability in the United States, this negative effect will likely affect highly competitive regions to a greater extent (25) .
It is often argued that many low MELD Na patients at high risk are not transplant candidates. In this study, we performed a subgroup analysis to examine mortality risk factors among patients with low MELD Na on the LT waiting list in the context of the broader population of low MELD Na patients with cirrhosis. We found that among patients with low MELD Na who were listed for LT, risk factors for mortality were the same as those for patients not listed; however, the effect of malnutrition (after adjusting for multiple variables including low albumin) was significantly greater for patients on the waitlist compared with patients not on the waitlist. For hepatic hydrothorax, the risk of death was increased in those not waitlisted, although not statistically significant for those on the waitlist.
A possible reason that hepatic hydrothorax confers an increased risk for nonwaitlisted patients might be the tendency of nontransplant professionals to attempt drainage, thus placing these patients at increased risk of complications. With regard to malnutrition, the risk of death for waitlisted patients that we observed was greater than shown in previously published reports. In the FrAILT study (26) , a cohort study evaluating functional decline in patients with cirrhosis awaiting LT, a Short Physical Performance Battery score <10 (a measure of malnutrition (27)) was associated with a waitlist mortality HR of 1.45 (95% CI 1.15-2.20). The HR in the FrAILT study is similar to the HR for nonwaitlisted patients in our study.
The effect of malnutrition among low MELD Na patients on the waitlist found in this study is of clinical importance. Not only is death on the waitlist significantly underestimated for these patients, malnutrition is independently associated with early post-LT mortality, and posttransplant outcomes may be poor if these patients undergo transplantation (28) . Posttransplant outcomes are not the focus of this study; however, the significant difference in risk observed between patients on the transplant waitlist compared with patients not waitlisted can be explained in part by waitlisting practices for patients with low MELD Na in the Chicago metropolitan area. Consequently, this study demonstrates that current waitlisting for patients with low MELD Na may, on the one hand, be limiting access for some patients while, on the other hand, selecting patients whose risk may be too great.
Given that very few patients with low MELD Na are waitlisted for LT, targeting patients with low MELD Na who are at high risk for evaluation is important. A lack of available organs is a significant barrier to deceased organ transplantation. This shortage means that, often, patients with low MELD Na have to "settle" for marginal organs; therefore, many transplant programs may not list low MELD Na patients because of concerns regarding poor outcomes and flagging by the Centers for Medicare and Medicaid Services. Living donor LT might offer a lifesaving alternative. Living donor LT has been shown to provide survival benefit for patients with MELD scores <15 (29) and is an underutilized resource in the United States. Greater effort can be made to identify patients with low MELD Na who may benefit from the procedure.
The analysis in this study cannot account for all factors taken into consideration for transplant waitlisting, such as ongoing substance abuse. We also cannot determine whether specific patients were referred or underwent transplant evaluation. We accept that not all high-risk patients with low MELD Na are actually transplant candidates, and if they are transplant candidates, not all may have living liver donors. Our analysis, however, provides evidence that the use of the MELD Na score for waitlisting may reduce access to LT for some high-risk patients and that low MELD Na patients currently waitlisted form a highly selected population of patients.
LT may not be the only management approach for highrisk patients with low MELD Na. In this study, we identified esophageal varices without bleeding as being associated with a reduced risk of death in the multivariate model. We postulate that these are patients for whom portal hypertension is diagnosed very early in the clinical course or who are receiving better medical management or both. It is also possible that this group of patients has a unique biological advantage in that they develop varices that do not tend to bleed. We hypothesize that among patients with low MELD, very early diagnosis of portal hypertension and improved care may prevent death, and LT may not be necessary.
Although early diagnosis of portal hypertension may reduce the risk of death, we found that patients with low MELD Na who underwent TIPS had an increased risk of death in the univariate model. In the multivariate model, TIPS was not statistically significant. A larger sample of patients with low MELD Na undergoing TIPS will be needed to fully identify whether TIPS reduces mortality in patients with low MELD Na and portal hypertension. This study has some limitations. It is retrospective and observational and prone to selection, information, and confounding biases (30) . Data from the Chicago metropolitan area were used; this is a highly competitive region with regard to available organs for LT. In addition, our data source cannot account for patients who transferred their care outside the Chicago metropolitan area; however, given that the data used in the study were obtained from different institutions, the population was diverse. Furthermore, follow-up in this study occurred over a period of 7 years, allowing the assessment of long-term survival.
Risk factors and complications were defined using various combinations of ICD-9 codes, CPT codes, laboratory values, and medications. Although these approaches have been validated in previous literature (13) (14) (15) 17) , they are limited by the quality of the medical records. It is possible that the definitions used in this study to capture risk factors and complications overemphasized some risk factors while underemphasizing others. Nevertheless, contrary to other population data sets, this study is novel because it captures information directly from the EHR as opposed to administrative data sets. EHRs have been shown to be better and more accurate sources of data for studies (31) .
Finally, the primary end point of this study was allcause mortality as opposed to liver-associated mortality. It is possible that some of the deaths observed in the study were unrelated to liver disease. A competing risk model that accounts for different causes of death could not be used in this study because data on cause of death were unavailable. To mitigate concern about disease severity unrelated to liver, the Elixhauser comorbidity index (18) was calculated for each patient. Overall, the study results are consistent with what would be expected clinically.
Although the allocation policy using the MELD Na score represents a step forward, persistent limitation should prompt the development of more comprehensive risk prediction tools in the future. The accurate identification of those patients at highest risk for mortality and their targeted selection for LT or other management modalities provides an opportunity to save additional lives.
